The potential of epigenetic therapies in neurodegenerative diseases

Frontiers in Genetics

Volumn 5, Issue JUL, 2014, Pages

  Coppedè, Fabio ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Alzheimer's disease; Amyotrophic lateral sclerosis; DNA methylation; Histone deacetylase inhibitors (HDACi); Histone tail modifications; Huntington's disease; Parkinson's disease; Therapeutic approaches

Indexed keywords

4 PHENYLBUTYRIC ACID; BUTYRIC ACID; DACINOSTAT; DJ 1 PROTEIN; ENTINOSTAT; NICOTINAMIDE; RILUZOLE; SIRTUIN 2; TRICHOSTATIN A; VALPROIC ACID; VORINOSTAT;

ALZHEIMER DISEASE; ARTICLE; DEGENERATIVE DISEASE; DNA METHYLATION; EPIGENETICS; HISTONE ACETYLATION; HISTONE METHYLATION; HUMAN; NONHUMAN; PARKINSON DISEASE; PHASE 2 CLINICAL TRIAL (TOPIC); VITAMIN SUPPLEMENTATION;

EID: 84906271313     PISSN: None     EISSN: 16648021     Source Type: Journal    
DOI: 10.3389/fgene.2014.00220     Document Type: Article

References (76)

1. Bakulski, K. M., Dolinoy, D. C., Sartor, M. A., Paulson, H. L., Konen, J. R., Lieberman, A. P., et al. (2012). Genome-wide DNA methylation differences between late-onset Alzheimer's disease and cognitively normal controls in human frontal cortex. J. Alzheimers Dis. 29, 571-588. doi: 10.3233/JAD-2012-111223
2. Berger, S. L. (2007). The complex language of chromatin regulation during transcription. Nature 447, 407-412. doi: 10.1038/nature05915
3. Bonifati, V., Rizzu, P., van Baren, M. J., Schaap, O., Breedveld, G. J., Krieger, E., et al. (2003). Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 299, 256-259. doi: 10.1126/science.1077209
4. Broide, R. S., Redwine, J. M., Aftahi, N., Young, W., Bloom, F. E., and Winrow, C. J. (2007). Distribution of histone deacetylases 1-11 in the ra tbrain. J. Mol. Neurosci. 31, 47-58. doi: 10.1007/bf02686117
5. Bürli, R. W., Luckhurst, C. A., Aziz, O., Matthews, K. L., Yates, D., Lyons, K. A., et al. (2013). Design, synthesis, and biological evaluation of potent and selective class IIa histone deacetylase (HDAC) inhibitors as a potential therapy for Huntington's disease. J. Med. Chem. 56, 9934-9954. doi: 10.1021/jm4011884
6. Chopra, V., Quinti, L., Kim, J., Vollor, L., Narayanan, K. L., Edgerly, C., et al. (2012). The sirtuin 2 inhibitor AK-7 is neuroprotective in Huntington's disease mouse models. Cell Rep. 2, 1492-1497. doi: 10.1016/j.celrep.2012.11.001
7. Chouliaras, L., Mastroeni, D., Delvaux, E., Grover, A., Kenis, G., Hof, P. R., et al. (2013). Consistent decrease in global DNA methylation and hydroxymethylation in the hippocampus of Alzheimer's disease patients. Neurobiol. Aging 34, 2091-2099. doi: 10.1016/j.neurobiolaging.2013.02.021
8. Coppedè, F. (2010). One-carbon metabolism and Alzheimer's disease: focus on epigenetics. Curr. Genomics 11, 246-260. doi: 10.2174/138920210791233090
9. Coppedè, F. (2012). Genetics and epigenetics of Parkinson's disease. ScientificWorldJournal 2012:489830. doi: 10.1100/2012/489830
10. Coppedè, F. (2014). Advances in the genetics and epigenetics of neurodegenerative diseases. Epigenetics Neurodegener. Dis. 1, 3-31. doi: 10.2478/end-2012-0002
11. Coppieters, N., Dieriks, B. V., Lill, C., Faull, R. L., Curtis, M. A., and Dragunow, M. (2014). Global changes in DNA methylation and hydroxymethylation in Alzheimer's disease human brain. Neurobiol. Aging 35, 1334-1344. doi: 10.1016/j.neurobiolaging.2013.11.031
12. Cudkowicz, M. E., Andres, P. L., Macdonald, S. A., Bedlack, R. S., Choudry, R., Brown, R. H. Jr., et al. (2009). Phase 2 study of sodium phenylbutyrate in ALS. Amyotroph. Lateral Scler. 10, 99-106. doi: 10.1080/17482960802320487
13. Del Signore, S. J., Amante, D. J., Kim, J., Stack, E. C., Goodrich, S., Cormier, K., et al. (2009). Combined riluzole and sodium phenylbutyrate therapy in transgenic amyotrophic lateral sclerosis mice. Amyotroph. Lateral Scler. 10, 85-94. doi: 10.1080/17482960802226148
14. Desplats, P., Spencer, B., Coffee, E., Patel, P., Michael, S., Patrick, C., et al. (2011). Alpha-synuclein sequesters Dnmt1 from the nucleus: a novel mechanism for epigenetic alterations in Lewy body diseases. J. Biol. Chem. 286, 9031-9037. doi: 10.1074/jbc.C110.212589
15. Ding, H., Dolan, P. J., and Johnson, G. V. (2008). Histone deacetylase 6 interacts with the microtubule-associated protein tau. J. Neurochem. 106, 2119-2130. doi: 10.1111/j.1471-4159.2008.05564.x
16. Douaud, G., Refsum, H., de Jager, C. A., Jacoby, R., Nichols, T. E., Smith, S. M., et al. (2013). Preventing Alzheimer's disease-related gray matter atrophy by B-vitamin treatment. Proc. Natl. Acad. Sci. U.S.A. 110, 9523-9528. doi: 10.1073/pnas.1301816110
17. Duan, W. (2013). Targeting sirtuin-1 in Huntington's disease: rationale and current status. CNS Drugs 27, 345-352. doi: 10.1007/s40263-013-0055-0
18. Feng, H. L., Leng, Y., Ma, C. H., Zhang, J., Ren, M., and Chuang, D. M. (2008). Combined lithium and valproate treatment delays disease onset, reduces neurological deficits and prolongs survival in an amyotrophic lateral sclerosis mouse model. Neuroscience 155, 567-572. doi: 10.1016/j.neuroscience.2008.06.040
19. Fischer, A. (2014). Targeting histone-modifications in Alzheimer's disease. What is the evidence that this is a promising therapeutic avenue? Neuropharmacology 80C, 95-102. doi: 10.1016/j.neuropharm.2014.01.038
20. Fischer, A., Sananbenesi, F., Wang, X., Dobbin, M., and Tsai, L. H. (2007). Recovery of learning and memory after neuronal loss is associated with chromatin remodeling. Nature 447, 178-182. doi: 10.1038/nature05772
21. Fournier, A., Sasai, N., Nakao, M., and Defossez, P. A. (2012). The role of methyl-binding proteins in chromatin organization and epigenome maintenance. Brief Funct. Genomics 11, 251-264. doi: 10.1093/bfgp/elr040
22. Francis, Y. I., Fà, M., Ashraf, H., Zhang, H., Staniszewski, A., Latchman, D. S., et al. (2009). Dysregulation of histone acetylation in the APP/PS1 mouse model of Alzheimer's disease. J. Alzheimers Dis. 18, 131-139. doi: 10.3233/JAD-2009-1134
23. Fuso, A., Nicolia, V., Cavallaro, R. A., Ricceri, L., D'Anselmi, F., Coluccia, P., et al. (2008). B-vitamin deprivation induces hyperhomocysteinemia and brain S-adenosylhomocysteine, depletes brain S-adenosylmethionine, and enhances PS1 and BACE expression and amyloid-beta deposition in mice. Mol. Cell Neurosci. 37, 731-746. doi: 10.1016/j.mcn.2007.12.018
24. Fuso, A., Nicolia, V., Ricceri, L., Cavallaro, R. A., Isopi, E., Mangia, F., et al. (2012). S-adenosylmethionine reduces the progress of the Alzheimer-like features induced by B-vitamin deficiency in mice. Neurobiol. Aging 33, 1482.e1-1482.e16. doi: 10.1016/j.neurobiolaging.2011.12.013
25. Fuso, A., Seminara, L., Cavallaro, R. A., D'Anselmi, F., and Scarpa, S. (2005). S-adenosylmethionine/homocysteine cycle alterations modify DNA methylation status with consequent deregulation of PS1 and BACE and beta-amyloid production. Mol. Cell Neurosci. 28, 195-204. doi: 10.1016/j.mcn.2004.09.007
26. Goers, J., Manning-Bog, A. B., McCormack, A. L., Millett, I. S., Doniach, S., Di Monte, D. A., et al. (2003). Nuclear localization of alpha-synuclein and its interaction with histones. Biochemistry 42, 8465-8471. doi: 10.1021/bi0341152
27. Govindarajan, N., Agis-Balboa, R. C., Walter, J., Sananbenesi, F., and Fischer, A. (2011). Sodium butyrate improves memory function in an Alzheimer's disease mouse model when administered at an advanced stage of disease progression. J. Alzheimers Dis. 26, 187-197. doi: 10.3233/JAD-2011-110080
28. Gräff, J., Rei, D., Guan, J. S., Wang, W. Y., Seo, J., Hennig, K. M., et al. (2012). An epigenetic blockade of cognitive functions in the neurodegenerating brain. Nature 483, 222-226. doi: 10.1038/nature10849
29. Gray, S. G. (2010). Targeting histone deacetylases for the treatment of Huntington's disease. CNS Neurosci. Ther. 16, 348-361. doi: 10.1111/j.1755-5949.2010.00184.x
30. Guo, J. U., Ma, D. K., Mo, H., Ball, M. P., Jang, M. H., Bonaguidi, M. A., et al. (2011a). Neuronal activity modifies the DNA methylation landscape in the adult brain. Nat. Neurosci. 14, 1345-1351. doi: 10.1038/nn.2900
31. Guo, J. U., Su, Y., Zhong, C., Ming, G. L., and Song, H. (2011b). Hydroxylation of 5-methylcytosine by TET1 promotes active DNA demethylation in the adult brain. Cell 145, 423-434. doi: 10.1016/j.cell.2011.03.022
32. Harrison, I. F., and Dexter, D. T. (2013). Epigenetic targeting of histone deacetylase: therapeutic potential in Parkinson's disease? Pharmacol. Ther. 140, 34-52. doi: 10.1016/j.pharmthera.2013.05.010
33. Jia, H., Kast, R. J., Steffan, J. S., and Thomas, E. A. (2012). Selective histone deacetylase (HDAC) inhibition imparts beneficial effects in Huntington's disease mice: implications for the ubiquitin-proteasomal and autophagy systems. Hum. Mol. Genet. 21, 5280-5293. doi: 10.1093/hmg/dds379
34. Jiang, H., Poirier, M. A., Liang, Y., Pei, Z., Weiskittel, C. E., Smith, W. W., et al. (2006). Depletion of CBP is directly linked with cellular toxicity caused by mutant huntingtin. Neurobiol. Dis. 23, 543-551. doi: 10.1016/j.nbd.2006.04.011
35. Jones, P. A. (2012). Functions of DNA methylation: islands, start sites, gene bodies and beyond. Nat. Rev. Genet. 13, 484-492. doi: 10.1038/nrg3230
36. Joshi, P., Greco, T. M., Guise, A. J., Luo, Y., Yu, F., Nesvizhskii, A. I., et al. (2013). The functional interactome landscape of the human histone deacetylase family. Mol. Syst. Biol. 9, 672. doi: 10.1038/msb.2013.26
37. Jowaed, A., Schmitt, I., Kaut, O., and Wüllner, U. (2010). Methylation regulates alpha-synuclein expression and is decreased in Parkinson's disease patients' brains. J. Neurosci. 30, 6355-6359. doi: 10.1523/JNEUROSCI.6119-09.2010
38. Karagiannis, T. C., and Ververis, K. (2012). Potential of chromatin modifying compounds for the treatment of Alzheimer's disease. Pathobiol. Aging Age Relat. Dis. 2:14980. doi: 10.3402/pba.v2i0.14980
39. Kilgore, M., Miller, C. A., Fass, D. M., Hennig, K. M., Haggarty, S. J., Sweatt, J. D., et al. (2010). Inhibitors of class 1 histone deacetylases reverse contextual memory deficits in a mouse model of Alzheimer's disease. Neuropsychopharmacology 35, 870-880. doi: 10.1038/npp.2009.197
40. Kontopoulos, E., Parvin, J. D., and Feany, M. B. (2006). Alpha-synuclein acts in the nucleus to inhibit histone acetylation and promote neurotoxicity. Hum. Mol. Genet. 15, 3012-3023. doi: 10.1093/hmg/ddl243
41. Lattal, K. W., and Wood, M. A. (2013). Epigenetics and persistent memory: implications for reconsolidation and silent extinction beyond the zero. Nat. Neurosci. 16, 124-129. doi: 10.1038/nn.3302
42. Lazo-Gómez, R., Ramírez-Jarquín, U. N., Tovar-y-Romo, L. B., and Tapia, R. (2013). Histone deacetylases and their role in motor neuron degeneration. Front. Cell. Neurosci. 7:243. doi: 10.3389/fncel.2013.00243
43. Lee, S., Lemere, C. A., Frost, J. L., and Shea, T. B. (2012). Dietary supplementation with S-adenosyl methionine delayed amyloid-ß and tau pathology in 3xTg-AD mice. J. Alzheimers Dis. 28, 423-431. doi: 10.3233/JAD-2011-111025
44. Luger, K., Mäder, A. W., Richmond, R. K., Sargent, D. F., and Richmond, T. J. (1997). Crystal structure of the nucleosome core particle at 2.8 A resolution. Nature 389, 251-260.
45. Martin, C., and Zhang, Y. (2005). The diverse functions of histone lysine methylation. Nat. Rev. Mol. Cell Biol. 6, 838-849. doi: 10.1038/nrm1761
46. Martín-Subero, J. I. (2011). How epigenomics brings phenotype into being. Pediatr. Endocrinol. Rev. S1, 506-510.
47. Mastroeni, D., Grover, A., Delvaux, E., Whiteside, C., Coleman, P. D., and Rogers, J. (2010). Epigenetic changes in Alzheimer's disease: decrements in DNA methylation. Neurobiol. Aging 31, 2025-2037. doi: 10.1016/j.neurobiolaging.2008.12.005
48. Matsumoto, L., Takuma, H., Tamaoka, A., Kurisaki, H., Date, H., Tsuji, S., et al. (2010). CpG demethylation enhances alphasynuclein expression and affects the pathogenesis of Parkinson's disease. PLoS ONE 5:e15522. doi: 10.1371/journal.pone.0015522
49. Migliore, L., and Coppedè, F. (2009). Genetics, environmental factors and the emerging role of epigenetics in neurodegenerative diseases. Mutat. Res. 667, 82-97. doi: 10.1016/j.mrfmmm.2008.10.011
50. Monti, B., Gatta, V., Piretti, F., Raffaelli, S. S., Virgili, M., and Contestabile, A. (2010). Valproic acid is neuroprotective in the rotenone rat model of Parkinson's disease: involvement of a-synuclein. Neurotox. Res. 17, 130-141. doi: 10.1007/s12640-009-9090-5
51. Nuytemans, K., Theuns, J., Cruts, M., and Van Broeckhoven, C. (2010). Genetic etiology of Parkinson disease associated with mutations in the SNCA, PARK2, PINK1, PARK7, and LRRK2 genes: a mutation update. Hum. Mutat. 31, 763-780. doi: 10.1002/humu.21277
52. Outeiro, T. F., Kontopoulos, E., Altmann, S. M., Kufareva, I., Strathearn, K. E., Amore, A. M., et al. (2007). Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson's disease. Science 317, 516-519. doi: 10.1126/science.1143780
53. Overk, C. R., and Masliah, E. (2014). Pathogenesis of synaptic degeneration in Alzheimer's disease and Lewy body disease. Biochem. Pharmacol. 88, 508-516. doi: 10.1016/j.bcp.2014.01.015
54. Piepers, S., Veldink, J. H., de Jong, S. W., van der Tweel, I., van der Pol, W. L., Uijtendaal, E. V., et al. (2009). Randomized sequential trial of valproic acid in amyotrophic lateral sclerosis. Ann. Neurol. 66, 227-234. doi: 10.1002/ana.21620
55. Puckett, R. E., and Lubin, F. D. (2011). Epigenetic mechanisms in experience-driven memory formation and behaviour. Epigenomics 3, 649-664. doi: 10.2217/epi.11.86
56. Rane, P., Shields, J., Heffernan, M., Guo, Y., Akbarian, S., and King, J. A. (2012). The histone deacetylase inhibitor, sodium butyrate, alleviates cognitive deficits in pre-motor stage PD. Neuropharmacology 62, 2409-2412. doi: 10.1016/j.neuropharm.2012.01.026
57. Ricobaraza, A., Cuadrado-Tejedor, M., Marco, S., Pérez-Otaño, I., and García-Osta, A. (2010). Phenylbutyrate rescues dendritic spine loss associated with memory deficits in a mouse model of Alzheimer disease. Hippocampus 22, 1040-1050. doi: 10.1002/hipo.20883
58. Rouaux, C., Panteleeva, I., René, F., Gonzalez de Aguilar, J. L., Echaniz-Laguna, A., Dupuis, L., et al. (2007). Sodium valproate exerts neuroprotective effects in vivo through CREB-binding protein-dependent mechanisms but does not improve survival in an amyotrophic lateral sclerosis mouse model. J. Neurosci. 27, 5535-5545. doi: 10.1523/JNEUROSCI.1139-07.2007
59. Ryu, H., Smith, K., Camelo, S. I., Carreras, I., Lee, J., Iglesias, A. H., et al. (2005). Sodium phenylbutyrate prolongs survival and regulates expression of anti-apoptotic genes in transgenic amyotrophic lateral sclerosis mice. J. Neurochem. 93, 1087-1098.
60. Sanchez-Mut, J. V., Aso, E., Panayotis, N., Lott, I., Dierssen, M., Rabano, A., et al. (2014). DNA methylation map of mouse and human brain identifies target genes in Alzheimer's disease. Brain 136, 3018-3027. doi: 10.1093/brain/awt237
61. Song, C., Kanthasamy, A., Anantharam, V., Sun, F., and Kanthasamy, A. G. (2010). Environmental neurotoxic pesticide increases histone acetylation to promote apoptosis in dopaminergic neuronal cells: relevance to epigenetic mechanisms of neurodegeneration. Mol. Pharmacol. 77, 621-632. doi: 10.1124/mol.109.062174
62. Song, C., Kanthasamy, A., Jin, H., Anantharam, V., and Kanthasamy, A. G. (2011). Paraquat induces epigenetic changes by promoting histone acetylation in cell culture models of dopaminergic degeneration. Neurotoxicology 32, 586-595. doi: 10.1016/j.neuro.2011.05.018
63. Steffan, J. S., Kazantsev, A., Spasic-Boskovic, O., Greenwald, M., Zhu, Y. Z., Gohler, H., et al. (2000). The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription. Proc. Natl. Acad. Sci. U.S.A. 97, 6763-6768. doi: 10.1073/pnas.100110097
64. St Laurent, R., O'Brien, L. M., and Ahmad, S. T. (2013). Sodium butyrate improves locomotor impairment and early mortality in a rotenone-induced Drosophila model of Parkinson's disease. Neuroscience 246, 382-390. doi: 10.1016/j.neuroscience.2013.04.037
65. Suchy, J., Lee, S., Ahmed, A., and Shea, T. B. (2010). Dietary supplementation with S-adenosyl methionine delays the onset of motor neuron pathology in a murine model of amyotrophic lateral sclerosis. Neuromolecular Med. 12, 86-97. doi: 10.1007/s12017-009-8089-7
66. Sugai, F., Yamamoto, Y., Miyaguchi, K., Zhou, Z., Sumi, H., Hamasaki, T., et al. (2004). Benefit of valproic acid in suppressing disease progression of ALS model mice. Eur. J. Neurosci. 20, 3179-3183. doi: 10.1111/j.1460-9568.2004.03765.x
67. Sultan, F. A., and Day, J. J. (2011). Epigenetic mechanisms in memory and synaptic function. Epigenomics 3, 157-181. doi: 10.2217/epi.11.6
68. Sung, Y. M., Lee, T., Yoon, H., DiBattista, A. M., Song, J., Sohn, Y., et al. (2013). Mercaptoacetamide-based class II HDAC inhibitor lowers Aß levels and improves learning and memory in a mouse model of Alzheimer's disease. Exp. Neurol. 239, 192-201. doi: 10.1016/j.expneurol.2012.10.005
69. Tchantchou, F., Graves, M., Falcone, D., and Shea, T. B. (2008). S-adenosylmethionine mediates glutathione efficacy by increasing glutathione S-transferase activity: implications for S-adenosyl methionine as a neuroprotective dietary supplement. J. Alzheimers Dis. 14, 323-328.
70. Thomas, B., and Beal, M. F. (2011). Molecular insights into Parkinson's disease. F1000 Med. Rep. 3, 7. doi: 10.3410/M3-7
71. Yoo, Y. E., and Ko, C. P. (2011). Treatment with trichostatin A initiated after disease onset delays disease progression and increases survival in a mouse model of amyotrophic lateral sclerosis. Exp. Neurol. 231, 147-159. doi: 10.1016/j.expneurol.2011.06.003
72. Zakhary, S. M., Ayubcha, D., Dileo, J. N., Jose, R., Leheste, J. R., Horowitz, J. M., et al. (2010). Distribution analysis of deacetylase SIRT1 in rodent and human nervous systems. Anat. Rec. (Hoboken) 293, 1024-1032. doi: 10.1002/ar.21116
73. Zhang, K., Schrag, M., Crofton, A., Trivedi, R., Vinters, H., and Kirsch, W. (2012). Targeted proteomics for quantification of histone acetylation in Alzheimer's disease. Proteomics 12, 1261-1268. doi: 10.1002/pmic.201200010
74. Zhang, Z., and Schluesener, Y. H. J. (2013). Oral administration of histone deacetylase inhibitor MS-275 ameliorates neuroinflammation and cerebral amyloidosis and improves behavior in a mouse model. J. Neuropathol. Exp. Neurol. 72, 178-185. doi: 10.1097/NEN.0b013e318283114a
75. Zhou, W., Bercury, K., Cummiskey, J., Luong, N., Lebin, J., and Freed, C. R. (2011). Phenylbutyrate up-regulates the DJ-1 protein and protects neurons in cell culture and in animal models of Parkinson disease. J. Biol. Chem. 286, 14941-14951. doi: 10.1074/jbc.M110.211029
76. Zhu, M., Li, W. W., and Lu, C. Z. (2014). Histone decacetylase inhibitors prevent mitochondrial fragmentation and elicit early neuroprotection against MPP+. CNS Neurosci. Ther. 20, 308-316. doi: 10.1111/cns.12217